Findings from a first-in-human phase I study investigating IBI363 – ESMO
ESMO shared on LinkedIn:
“ESMO Virtual Plenary: Findings from a first-in-human phase I study investigating IBI363, a PD-1/IL-2 bispecific antibody fusion protein, provide proof-of-concept on its capacity to revert acquired resistance to immunotherapy in pre-treated patients and in some populations with a poor prognosis including patients with Mucosal Melanoma.
According to Alberto Hernando Calvo, additional work remains to be conducted to fully elucidate the subset of patients who may derive benefit from IBI363, but indeed the data presented support further investigation to pave the way for designing novel IL-2-based immunotherapy combinations in the anti-PD-1/L1 resistant setting.
Read the full commentary on the ESMO Daily Reporter.”
Source: ESMO/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023